Loading...
•
Sep 30, 2020
Bristol-Myers Squibb Q3 2020 Earnings Report
Reported strong product sales, continued pipeline advancement, and robust operating performance
Key Takeaways
Bristol Myers Squibb reported a significant increase in third-quarter revenue, driven by the Celgene acquisition. The company's GAAP EPS was $0.82, and non-GAAP EPS was $1.63. They are also planning to acquire MyoKardia to strengthen cardiovascular franchise.
Third quarter revenues reached $10.5 billion, a 75% increase.
GAAP EPS was reported at $0.82, while non-GAAP EPS reached $1.63.
The company is planning the acquisition of MyoKardia to extend and strengthen the cardiovascular franchise.
Positive results were achieved from the POETYK-PSO-1 trial evaluating deucravacitinib for plaque psoriasis.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb Revenue by Segment
Revenue by Segment
Net Product Sales Revenue
CapyFin.comAlliance and Other Revenues Revenue
CapyFin.com Forward Guidance
Bristol Myers Squibb is increasing its 2020 GAAP EPS guidance range from ($0.06) - $0.09 to $0.47 - $0.57. In addition, the company is raising its 2020 non-GAAP EPS guidance range from $6.10 - $6.25 to $6.25 - $6.35 and reaffirming its 2021 non-GAAP EPS guidance range of $7.15 to $7.45.
Positive Outlook
- Revenue: $41.5B - $42.0B
- Gross margin as a percentage of revenue: Approximately 80%
- Marketing, selling, and administrative expense: Approximately $6.9B
- Research and development expense: Approximately $9.2B
- Effective tax rate: Approximately 16%
Revenue & Expenses
Visualization of income flow from segment revenue to net income